Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jeffrey G. Supko, Ph.D.

Co-Author

This page shows the publications co-authored by Jeffrey Supko and Patrick Wen.
Connection Strength

0.501
  1. Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-ß tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 2017 04 01; 19(4):567-575.
    View in: PubMed
    Score: 0.198
  2. Hochberg FH, Supko J, Amato A, Salem N, Carminati P, Wen P. Phase I trial and pharmacokinetic study of oral gimatecan in adults with malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1559.
    View in: PubMed
    Score: 0.094
  3. Supko JG, Alderson L, Wen P, Cassidy K, Pace S, Obrocea M, Hochberg F. Pharmacokinetics of gimatecan, and orally administered camptothecin analogue, in patients with malignant gliomas. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2039.
    View in: PubMed
    Score: 0.082
  4. Grossman SA, Romo CG, Rudek MA, Supko J, Fisher J, Nabors LB, Wen PY, Peereboom DM, Ellingson BM, Elmquist W, Barker FG, Kamson D, Sarkaria JN, Timmer W, Bindra RS, Ye X. Baseline Requirements for Novel Agents Being Considered for Phase II/III Brain Cancer Efficacy Trials:Conclusions from the Adult Brain Tumor Consortium's First Workshop on CNS Drug Delivery. Neuro Oncol. 2020 Jun 07.
    View in: PubMed
    Score: 0.062
  5. Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG, Hochberg F. A phase II trial of oral gimatecan for recurrent glioblastoma. J Neurooncol. 2013 Feb; 111(3):347-53.
    View in: PubMed
    Score: 0.037
  6. Hu J, Wen PY, Abrey LE, Fadul C, Drappatz J, Salem N, Amato A, Carminati P, Supko J, Hochberg F. Phase II trial of oral gimatecan in adults with recurrent glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2009.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.